ascopubs.org: Plasma metabolomic signatures for predicting pancreatic ductal adenocarcinoma survival: The clinical application of targeted mass spectrometry lipidomics. Plasma metabolomic signatures for predicting pancreatic ductal adenocarcinoma survival: The clinical application of targeted mass spectrometry lipidomics. Eraglusib combined with gemcitabine and nab-paclitaxel significantly improved overall survival in metastatic pancreatic ductal adenocarcinoma patients.
The combination therapy showed a favorable ... MedPage Today: Survival in Unresectable Pancreatic Cancer Improved With Tumor Treating Fields CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved significantly versus chemotherapy with the addition of tumor treating fields ... Medical Xpress on MSN: Discovery of pancreatic tumor vulnerability could pave the way for new treatments A team from the Research Institute of the McGill University Health Center (The Institute), led by Jean-Jacques Lebrun, Ph.D., has identified a protein that pancreatic cancer cells rely on to survive ... Discovery of pancreatic tumor vulnerability could pave the way for new treatments
